ReviewThe Korean journal of internal medicine2020
Distinct functions of eosinophils in severe asthma with type 2 phenotype: clinical implications.
Review in The Korean journal of internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Differences in Type 2 Phenotype and Clinical Characteristics of Adult Asthma Patients with Different Severity, Across GINA Step 1 to 5 Asthma.Journal of asthma and allergy · 2026Article
- Distinct Roles Between Eotaxin 1 and Eotaxin 2 in Asthmatic Airways.Clinical and translational allergy · 2025Article
- Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study.Journal of clinical medicine · 2025Article
- Aurantio-Obtusin Suppresses Airway Inflammation and Serum ICAM-1 Expression in Guinea Pig Allergic Asthma Model.Immunity, inflammation and disease · 2025Article
- The role of extracellular traps released by neutrophils, eosinophils, and macrophages in asthma.Respiratory research · 2024Review
- Association between specific IgE to staphylococcal enterotoxin B and the eosinophilic phenotype of asthma.The Korean journal of internal medicine · 2024Article
- Immune Cell-Mediated Autoimmune Responses in Severe Asthma.Yonsei medical journal · 2024Review
- New targets for type 2-low asthma.The Korean journal of internal medicine · 2024Review
- Bacterial Extracellular Vesicles: A Candidate Molecule for the Diagnosis and Treatment of Allergic Diseases.Allergy, asthma & immunology research · 2023Review
- Micrococcus luteus-derived extracellular vesicles attenuate neutrophilic asthma by regulating miRNAs in airway epithelial cells.Experimental & molecular medicine · 2023Article
- Immunologic Basis of Type 2 Biologics for Severe Asthma.Immune network · 2022Review
- Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma.Biomedicines · 2022Review
- Epithelial Autoantigen-Specific IgG Antibody Enhances Eosinophil Extracellular Trap Formation in Severe Asthma.Allergy, asthma & immunology research · 2022Article
- Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice.Journal of personalized medicine · 2022Review
- Immunoregulatory effects of Lactococcus lactis-derived extracellular vesicles in allergic asthma.Clinical and translational allergy · 2022Article
- The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions.Current research in immunology · 2022Review
- Extracellular Traps: A Novel Therapeutic Target for Severe Asthma.Journal of asthma and allergy · 2022Review
- Early Prediction of Severe COVID-19 in Patients by a Novel Immune-Related Predictive Model.mSphere · 2021Article
- Titanium Dioxide Nanoparticles Exacerbate Allergic Airway Inflammation via TXNIP Upregulation in a Mouse Model of Asthma.International journal of molecular sciences · 2021Article
- Biomarkers for Severe Asthma: Lessons From Longitudinal Cohort Studies.Allergy, asthma & immunology research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is commonly recognized as a heterogeneous condition with a complex pathophysiology. With advances in the development of multiple medications for patients with asthma, most asthma symptoms are well managed. Nevertheless, 5% to 10% of adult asthmatic patients (called severe asthma) are in uncontrolled or partially controlled status despite intensive treatment. Especially, severe eosinophilic asthma is one of the severe asthma phenotypes characterized by eosinophilia in sputum/blood driven by type 2 immune responses. Eosinophils have been widely accepted as a central effector cell in the lungs. Some evidence has demonstrated that persistent eosinophilia in upper and lower airway mucosa contributes to asthma severity by producing various mediators including cytokines, chemokines and granule proteins. Moreover, extracellular traps released from eosinophils have been revealed to enhance type 2 inflammation in patients with severe asthma. These novel molecules have the ability to induce airway inf lammation and hyperresponsiveness through enhancing innate and type 2 immune responses. In this review, we highlight recent insight into the function of eosinophil extracellular traps in patients with severe asthma. In addition, the role of eosinophil extracellular vesicles in severe asthma is also proposed. Finally, current biologics are suggested as a potential strategy for effective management of severe eosinophilic asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.